LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

103.29 -2.37

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

99.21

Max

106.75

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.2M

-93M

Verkäufe

33M

265M

Gewinnspanne

-34.965

Angestellte

1,999

EBITDA

6.6M

-82M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+24.29% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.6B

14B

Vorheriger Eröffnungskurs

105.66

Vorheriger Schlusskurs

103.29

Nachrichtenstimmung

By Acuity

50%

50%

159 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Feb. 2026, 17:37 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20. Feb. 2026, 16:18 UTC

Wichtige Markttreiber

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20. Feb. 2026, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. Feb. 2026, 22:12 UTC

Ergebnisse

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. Feb. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Feb. 2026, 21:23 UTC

Ergebnisse

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. Feb. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. Feb. 2026, 21:01 UTC

Akquisitionen, Fusionen, Übernahmen

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. Feb. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20. Feb. 2026, 20:17 UTC

Market Talk

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20. Feb. 2026, 20:11 UTC

Market Talk

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20. Feb. 2026, 19:59 UTC

Market Talk

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20. Feb. 2026, 19:58 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20. Feb. 2026, 19:49 UTC

Market Talk

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20. Feb. 2026, 19:09 UTC

Market Talk

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20. Feb. 2026, 19:00 UTC

Market Talk

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20. Feb. 2026, 18:28 UTC

Market Talk

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20. Feb. 2026, 18:20 UTC

Market Talk

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20. Feb. 2026, 18:05 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. Feb. 2026, 18:04 UTC

Market Talk

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20. Feb. 2026, 17:38 UTC

Market Talk

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20. Feb. 2026, 17:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Feb. 2026, 17:24 UTC

Market Talk

Correction to Treasury Yields Fall Market Talk

20. Feb. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

20. Feb. 2026, 16:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. Feb. 2026, 16:53 UTC

Market Talk

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20. Feb. 2026, 16:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Feb. 2026, 16:45 UTC

Market Talk

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20. Feb. 2026, 16:40 UTC

Market Talk

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

24.29% Vorteil

12-Monats-Prognose

Durchschnitt 132.22 USD  24.29%

Hoch 175 USD

Tief 110 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

19

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

159 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat